| Hao, Jihui |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
BESTPOP, NCT05594927: Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, ) |
|
|
| Recruiting | 3 | 261 | RoW | Icaritin, Huachansu | Beijing Shenogen Biomedical Co., Ltd | Hepatocellular Carcinoma | 08/25 | 08/25 | | |
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. |
|
|
| Recruiting | 3 | 220 | RoW | Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide. | Jiangsu HengRui Medicine Co., Ltd. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | 12/26 | 10/30 | | |
2023-012-00CH1, NCT06361888: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 482 | RoW | Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine | Hutchmed | Metastatic Pancreatic Cancer | 08/27 | 08/27 | | |
NCT05208177: A Study of SHR-1802 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 2 | 124 | RoW | SHR-1802＋camrelizumab + famitinib | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05559541: Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 102 | RoW | AK119, AK104 | Akeso | Solid Tumor, Adult | 03/24 | 09/24 | | |
| Active, not recruiting | 1/2 | 220 | RoW | SHR-A1921； | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 02/26 | | |
NCT05868876: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1a/1b | 205 | RoW | AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion | Akeso | Advanced Malignant Tumors | 11/25 | 02/26 | | |
NCT04482257: Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. |
|
|
| Recruiting | 1 | 48 | RoW | Irinotecan Liposome Injection combined with 5-FU/LV | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Pancreatic Cancer | 12/20 | 03/21 | | |
NCT05173792: Study of AK119 in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 16 | RoW | AK119 | Akeso | Solid Tumor | 05/23 | 05/23 | | |
NCT05149027: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1 | 67 | NA | HBM4003 and Triprilimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 05/24 | 05/24 | | |
NCT05125523: A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 264 | RoW | Sirolimus for Injection (Albumin Bound) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 06/24 | 11/24 | | |
| Recruiting | 1 | 65 | RoW | TQB3824 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 08/24 | 12/24 | | |
NCT05740202: A Trial of SHR-7367 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 182 | RoW | SHR-7367 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 11/25 | 11/25 | | |
